Search PubMed⌕ Search

Biomedical subjects

Sibu P Saha

Publications and source records attributed to Sibu P Saha.

5 recordsLinked to original sources

Cost management of coronary artery bypass surgery.

Coronary artery bypass is one of the most expensive operative procedures in the US. Considerable cost variation exists among hospitals across the country, and considerable variation in supply cost exists among surgeons. Implementation of "Best Practice Model" can reduce variable cost as much as $1300 per patient. Cost reduction is possible without sacrificing quality and outcome. Hospitals should develop a specialized team of stakeholders to manage cost and quality of coronary artery bypass surgery. Coronary artery bypass surgery is one of the most frequently performed operations in the US, and also one of the largest resource drains in our healthcare system. The purpose of this research is to examine hospital costs for coronary artery bypass surgery and to identify opportunities to reduce costs without sacrificing quality and outcome.

Benchmarking↗

Adjunctive transmyocardial revascularization: five-year follow-up of a prospective, randomized trial.

BACKGROUND: In a prospective, randomized trial involving 263 patients who would be incompletely revascularized by coronary artery bypass grafting (CABG) alone, CABG plus transmyocardial revascularization (CABG/TMR) provided an early mortality benefit with similar angina relief compared with CABG alone at 1 year. We evaluated the long-term outcome of patients randomized to CABG/TMR or CABG alone. METHODS: Thirteen centers that enrolled 83% (218/263) of the patients in the original trial participated in this longitudinal study. Between 1996 and 1998, these centers randomized 218 patients who would be incompletely revascularized by CABG alone because of diffusely diseased target vessels to either holmium:yttrium-aluminum-garnet (holmium:YAG) CABG/TMR (n = 110) or CABG alone (n = 108). Baseline demographics and operative characteristics were similar between groups. Follow-up (mean 5.0 +/- 1.7 years) included survival and blinded angina class assessment. RESULTS: At this 5-year follow-up both groups experienced significant angina improvement from baseline, however, the CABG/TMR group had a lower mean angina score (0.4 +/- 0.7 vs 0.7 +/- 1.1, p = 0.05), a significantly lower proportion of patients with severe angina (class III/IV: 0% [0/68] vs 10% [6/60], p = 0.009), and a trend towards greater number of angina-free patients (78% [53/68] vs 63% [38/60], p = 0.08), compared with CABG alone patients. Kaplan-Meier survival at 6 years was similar between CABG/TMR and CABG alone patients (76% vs 80%, p = 0.90). CONCLUSIONS: Five-year follow-up of prospectively randomized patients who would be incompletely revascularized because of diffuse coronary artery disease indicates that the addition of TMR to conventional CABG provides superior angina relief compared to CABG alone.

Aged↗

Pulmonary carcinosarcoma.

Pulmonary carcinosarcoma is a rare malignancy, comprising less than 0.3% of all malignant neoplasms of the lung. Since the first report of this tumor by Kika in 1908, approximately 100 cases have been described in the literature. In this report, we present five cases treated by our group over a period of 20 years.

Aged↗

Primary pulmonary rhabdomyosarcoma: a long-term survivor.

This is a clinical report of a young girl who presented with a large left lung mass, which was found to be alveolar rhabdomyosarcoma, a rare clinical entity. This was successfully treated with surgery, radiation, and chemotherapy. To our knowledge, this is the longest survivor with this disease.

Adolescent↗